These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20142330)

  • 41. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa.
    Italiano A; Delcambre C; Hostein I; Cazeau AL; Marty M; Avril A; Coindre JM; Bui B
    Ann Oncol; 2010 May; 21(5):1135-7. PubMed ID: 20215136
    [No Abstract]   [Full Text] [Related]  

  • 42. Focusing on the role of protein kinase mTOR in endometrial physiology and pathology: insights for therapeutic interventions.
    Wang B; Gao M; Yao Y; Li H; Zhang X
    Mol Biol Rep; 2024 Feb; 51(1):359. PubMed ID: 38400863
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.
    Andrade-Vieira R; Goguen D; Bentley HA; Bowen CV; Marignani PA
    Oncotarget; 2014 Dec; 5(24):12738-52. PubMed ID: 25436981
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.
    Mallon R; Hollander I; Feldberg L; Lucas J; Soloveva V; Venkatesan A; Dehnhardt C; Delos Santos E; Chen Z; Dos Santos O; Ayral-Kaloustian S; Gibbons J
    Mol Cancer Ther; 2010 Apr; 9(4):976-84. PubMed ID: 20371716
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
    Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
    J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt.
    Li Y; Yang DQ
    Mol Cancer Ther; 2010 Jan; 9(1):113-25. PubMed ID: 20053781
    [TBL] [Abstract][Full Text] [Related]  

  • 48. LKB1 modulates lung cancer differentiation and metastasis.
    Ji H; Ramsey MR; Hayes DN; Fan C; McNamara K; Kozlowski P; Torrice C; Wu MC; Shimamura T; Perera SA; Liang MC; Cai D; Naumov GN; Bao L; Contreras CM; Li D; Chen L; Krishnamurthy J; Koivunen J; Chirieac LR; Padera RF; Bronson RT; Lindeman NI; Christiani DC; Lin X; Shapiro GI; Jänne PA; Johnson BE; Meyerson M; Kwiatkowski DJ; Castrillon DH; Bardeesy N; Sharpless NE; Wong KK
    Nature; 2007 Aug; 448(7155):807-10. PubMed ID: 17676035
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Kinome Profiling of Primary Endometrial Tumors Using Multiplexed Inhibitor Beads and Mass Spectrometry Identifies SRPK1 as Candidate Therapeutic Target.
    Kurimchak AM; Kumar V; Herrera-Montávez C; Johnson KJ; Srivastava N; Davarajan K; Peri S; Cai KQ; Mantia-Smaldone GM; Duncan JS
    Mol Cell Proteomics; 2020 Dec; 19(12):2068-2090. PubMed ID: 32994315
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MIG-6 negatively regulates STAT3 phosphorylation in uterine epithelial cells.
    Yoo JY; Yang WS; Lee JH; Kim BG; Broaddus RR; Lim JM; Kim TH; Jeong JW
    Oncogene; 2018 Jan; 37(2):255-262. PubMed ID: 28925396
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LKB1 loss at transcriptional level promotes tumor malignancy and poor patient outcomes in colorectal cancer.
    He TY; Tsai LH; Huang CC; Chou MC; Lee H
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S703-10. PubMed ID: 24879590
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models.
    Squillace RM; Miller D; Cookson M; Wardwell SD; Moran L; Clapham D; Wang F; Clackson T; Rivera VM
    Mol Cancer Ther; 2011 Oct; 10(10):1959-68. PubMed ID: 21825008
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro.
    Darb-Esfahani S; Faggad A; Noske A; Weichert W; Buckendahl AC; Müller B; Budczies J; Röske A; Dietel M; Denkert C
    J Cancer Res Clin Oncol; 2009 Jul; 135(7):933-41. PubMed ID: 19107520
    [TBL] [Abstract][Full Text] [Related]  

  • 54. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.
    Shaw RJ
    Acta Physiol (Oxf); 2009 May; 196(1):65-80. PubMed ID: 19245654
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.
    Ayral-Kaloustian S; Gu J; Lucas J; Cinque M; Gaydos C; Zask A; Chaudhary I; Wang J; Di L; Young M; Ruppen M; Mansour TS; Gibbons JJ; Yu K
    J Med Chem; 2010 Jan; 53(1):452-9. PubMed ID: 19928864
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The SGK1 inhibitor SI113 induces autophagy, apoptosis, and endoplasmic reticulum stress in endometrial cancer cells.
    Conza D; Mirra P; Calì G; Tortora T; Insabato L; Fiory F; Schenone S; Amato R; Beguinot F; Perrotti N; Ulianich L
    J Cell Physiol; 2017 Dec; 232(12):3735-3743. PubMed ID: 28177128
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
    Takeuchi H; Kondo Y; Fujiwara K; Kanzawa T; Aoki H; Mills GB; Kondo S
    Cancer Res; 2005 Apr; 65(8):3336-46. PubMed ID: 15833867
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma.
    Koivisto CS; Parrish M; Bonala SB; Ngoi S; Torres A; Gallagher J; Sanchez-Hodge R; Zeinner V; Nahhas GJ; Liu B; Cohn DE; Backes FJ; Goodfellow PJ; Chamberlin HM; Leone G
    Neoplasia; 2020 Oct; 22(10):484-496. PubMed ID: 32818842
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inactivation of
    Zhou S; Li Y; Qiao L; Ge Y; Huang X; Gao X; Ju H; Wang W; Zhang J; Yan J; Teng H; Jiang Q
    FASEB J; 2019 Aug; 33(8):9476-9488. PubMed ID: 31091421
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
    Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
    PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.